You've read enough about GLP-1 medications to know they exist, know they affect blood sugar, and know a lot of people with insulin resistance or type 2 diabetes are using them. That part's settled in your head. What's stopping you is the boring stuff. The price. Whether your plan covers anything. Whether the side effects you've heard about are the norm or the outlier. Whether a video visit with a clinician you've never met in person counts as real care.
Fair questions. Let me answer them the way I'd want them answered.
The short version: what you pay depends almost entirely on your diagnosis codes and your plan's formulary, not on your motivation. Most side effects are gastrointestinal, dose-related, and manageable with a slow titration. And if you're already taking insulin or a sulfonylurea, there's one specific safety conversation you need to have before day one. None of that is a reason to stay stuck. All of it is a reason to ask better questions.
Why I take this question seriously
I co-founded tb2.health, and I was also its first patient. Patient zero. Which means I've sat on both sides of this: the guy building the intake flow, and the guy staring at a fasting glucose number he didn't love, wondering whether he was about to spend a fortune to find out he wasn't eligible.
I'm not a clinician. I want that on the table early and I'll repeat it later. What I am is someone who has read an absurd number of formulary documents and sat in on enough patient calls to know which worries are legitimate and which ones dissolve the moment somebody explains the mechanics.
Cost is legitimate. Hypoglycemia risk when you're already on glucose-lowering medication is legitimate. "I'm scared I'll fail at this too" is legitimate, and we'll get to it. "Telehealth isn't real medicine" mostly dissolves.
Cost and insurance coverage: what actually determines your price
Here's the uncomfortable truth about GLP-1 pricing in the U.S.: two people on the same medication, at the same dose, in the same zip code, can pay wildly different amounts. That's not a conspiracy. It's formulary design.
KFF's polling has consistently found that cost is the single biggest barrier for adults interested in these medications, and that coverage varies enormously by plan type and by the reason the drug is prescribed. That last part is the key. Coverage for a GLP-1 prescribed for type 2 diabetes management and coverage for one prescribed for weight management are treated as two different things by most payers.
The three questions that decide what you pay
- What's your documented diagnosis? Type 2 diabetes, prediabetes, insulin resistance without a formal diabetes diagnosis, and obesity with comorbidities are four different conversations with a payer.
- Does your plan include a weight-management or anti-obesity drug benefit? Many employer plans carve it out entirely. Some require documented prior attempts at lifestyle intervention. Some require prior authorization with lab values attached.
- What does the self-pay market look like for you right now? Manufacturer direct-purchase programs launched in 2025 changed cash pricing meaningfully, and compounded options tightened up after the FDA declared the semaglutide and tirzepatide shortages resolved. The self-pay landscape in 2026 is genuinely different from the one your neighbor navigated in 2023.
Where coverage usually comes from
| Your situation | Typical coverage pathway | What to ask your plan |
|---|---|---|
| Employer plan, type 2 diabetes diagnosis | Often covered on the medical/diabetes side of the formulary, frequently with prior authorization | "Is this drug on formulary for T2D? What tier? What are the PA criteria?" |
| Employer plan, insulin resistance or prediabetes only | Frequently excluded; may fall under a weight-management carve-out if one exists | "Does my plan have an anti-obesity medication benefit? What BMI or comorbidity criteria apply?" |
| Medicare Part D | Historically excluded drugs used for weight loss; coverage has existed when prescribed for type 2 diabetes. Federal policy in this area has been actively changing, so verify current status | "Is this covered under my specific Part D plan for my diagnosis this plan year?" |
| Medicaid | Varies dramatically state to state | Check your state's preferred drug list directly |
| No coverage at all | Self-pay, including manufacturer direct programs and telehealth program pricing | "What's the all-in monthly cost including clinical supervision, not just the vial?" |
That last question matters more than people realize. A low advertised drug price with no clinical follow-up attached isn't cheaper. It's just unbundled. We at TB2 Health price the program as a program: the medication plus the physician oversight, dose adjustments, and check-ins, because splitting those apart is how people end up titrating alone at 11pm with a search engine.
Two practical moves before you spend an hour on hold. Pull your plan's formulary PDF (it's usually public on the member portal) and search it. Then call the member services number on your card and ask the exact questions in the table above, in that order. Write down the reference number for the call. You'd be surprised how often the second rep gives a different answer than the first.
Safety when insulin resistance is already in the picture
This is where the Confidence & Access conversation gets specific for you, because starting a GLP-1 when your glucose metabolism is already impaired is not identical to starting one otherwise.
What side effects actually look like
The most common adverse effects across the clinical trial literature are gastrointestinal: nausea, vomiting, diarrhea, constipation. In the large cardiovascular and glycemic trials for GLP-1 receptor agonists, GI effects were the leading reason participants discontinued, and they were largely dose-dependent and most pronounced during dose escalation. That's the pattern the FDA-approved labeling for these agents reflects, and it's why titration schedules exist at all.
Practical version, from someone who has been through the escalation:
Eat smaller portions and stop early. Hydrate, genuinely, more than you think. Prioritize protein so you're not losing muscle along with fat. Don't hero your way through a dose increase because you want to move faster. Slower titration is not failure, it's the actual protocol.
Rarer but serious risks documented in labeling include pancreatitis, gallbladder disease, and a boxed warning regarding thyroid C-cell tumors observed in rodents, which is why a personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. Those are clinician conversations, not internet conversations.
Hypoglycemia: the one to flag before day one
GLP-1 receptor agonists stimulate insulin release in a glucose-dependent way, which means on their own they carry low hypoglycemia risk. Combined with insulin or a sulfonylurea, the risk rises. The American Diabetes Association's Standards of Care addresses this directly: when adding a GLP-1 receptor agonist, clinicians commonly reduce the dose of background insulin or sulfonylurea to reduce hypoglycemia risk.
So if you're currently on either of those, that's the first thing you tell the prescribing clinician. Not the fifth. And ask how you'll be monitored during titration, whether you should be checking glucose more often, and what number should trigger a call.
There's also a caution worth naming for people with existing diabetic retinopathy: rapid improvement in glucose control can be associated with temporary worsening of retinopathy. Your clinician needs to know your eye exam history. This is exactly the kind of detail that gets missed when care is fragmented.
What a virtual visit actually involves
If your mental image is a two-minute chat and a prescription, that's not what a legitimate program looks like, and it's not what ours looks like.
Expect a structured intake covering medical history, current medications, family history, and prior treatment attempts. Expect to be asked for recent labs, and if you don't have recent labs, expect to be asked to get them. A1c, comprehensive metabolic panel, lipids, sometimes thyroid function. Expect a licensed clinician in your state to review all of it and decide on eligibility, starting dose, and titration schedule.
Expect follow-up. That's the part that separates a program from a transaction. Dose changes, side effect management, adjustments to background diabetes medications, and periodic lab rechecks are the actual clinical work.
And expect to be told no, sometimes. Contraindications exist. A program that never declines anyone isn't screening anyone.
The part nobody puts in the brochure
You may have a history here. Attempts that didn't hold. Advice from a clinician that landed as blame. A relationship with food and with your own body that got complicated somewhere around the third or fourth time a plan stopped working.
Insulin resistance carries a particular sting because it feels like your body is working against you, and because for years the cultural narrative treated it as a character flaw. It isn't. It's physiology, with genetics, sleep, stress, medications, and age all pulling levers.
Starting treatment anxiety is normal. So is the quiet fear that you'll start, struggle with nausea in week three, and conclude you failed again. Name that fear out loud on your first call. The good clinicians have heard it a thousand times and they'll plan around it.
Where clinicians come in, and where I don't
I'll say it plainly. I'm not a clinician. Nothing here is a diagnosis, a prescription, or a substitute for an evaluation by someone licensed to give you one. If you have type 2 diabetes, insulin resistance, or any other metabolic diagnosis, decisions about starting, stopping, or adjusting any medication belong to your prescribing clinician and your care team, in conversation with you.
That's not a liability hedge. It's the thing I actually believe. The value of a supervised program is that somebody with credentials is watching your labs, your doses, and your background medications at the same time. Take advantage of that. Ask the awkward questions. Ask for the reasoning behind the plan.
Your next thirty minutes
Pull the formulary. Make the call to member services. Write down your current medication list, including doses, because you'll need it. If you have labs from the past six months, find them.
That's it. That's the whole first step, and it costs nothing but a slightly annoying phone call. You don't have to decide anything today. You just have to stop guessing at the numbers.
The uncertainty is the heavy part, and uncertainty is solvable. If you want help walking through eligibility and what a supervised plan would actually involve for someone with your history, we're here at tb2.health, and the first conversation is a conversation, not a commitment.
Paul Moss Co-founder, tb2.health
This article is educational and is not medical advice. Individual results and eligibility vary. Talk with a licensed clinician about your specific health history before starting, stopping, or changing any medication.
